Loading patent…
AssigneeRoskamp Research Institute, LLC
InventorsJun Tan, Terrence Town, Michael Mullan
Estimating the term…
There is provided an assay method for determining the effect of an agent on Alzheimer's Disease pathology by treating microglial cells with Aβ peptides, adding CD40 ligand to the microglial cells, adding a therapeutic agent to the microglial cells, and measuring Alzheimer's Disease pathology. Also provided is a method of determining therapeutic effectiveness of an agent for Alzheimer's Disease by measuring the inhibition of CD40-CD40L binding in the presence of the agent. An assay for determining the effect of an agent on Alzheimer's Disease pathology having Aβ peptides for adding to microglial cells, CD40 ligand for being added to the microglial cells, a therapeutic agent being added to the microglial cells and a measuring device for reassuring Alzheimer's Disease pathology is also provided.
An in vitro assay method for determining the effect of an agent on Alzheimer's disease pathology comprising the steps of:
A method of determining therapeutic effectiveness of an agent for Alzheimer's disease comprising the step of measuring in vitro the inhibition of the CD40-CD40L binding in the presence of the agent and correlating any increase in inhibition of CD40-CD40L binding to an increase in effectiveness of the agent for Alzheimer's disease, followed by measuring the agent's effectiveness in reducing Alzheimer's disease pathology.
An in vitro assay kit for determining the effect of an agent on Alzheimer's disease pathology comprising:
Dependencies are inferred from the claim text.